CA-BELKIN
28.6.2022 21:02:05 CEST | Business Wire | Press release
Belkin , a consumer electronics leader, today announced the revamped BOOSTCHARGE PRO 3-in-1 Wireless Charging Stand upgraded to support fast charging on Apple Watch Series 7, which charges from 0 to 80% in about 45 minutes, up to 33% faster than Series 6**. In a familiar form factor to the product launched in 2020, this upgraded version will deliver the same functionality to iPhone 13 and iPhone 12 models, AirPods Pro and AirPods with Wireless Charging Case.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005013/en/
Key features:
- Supports fast charging for Apple Watch Series 7
- "Made for MagSafe” engineered to provide up to 15W of charging power to iPhone 13 and iPhone 12 models***
- Provides 5W charging power for AirPods Pro and AirPods with Wireless Charging Case
- MagSafe stand for iPhone features a non-slip design to support iPhone 13 or iPhone 12 models in portrait or landscape mode and is compatible with MagSafe cases up to 3mm thick
- Includes 2-year warranty and Belkin Connected Equipment Warranty up to $2,500
- Includes 40W power supply unit
AVAILABILITY AND PRICING
Available in Apple stores (Americas and Asia) in June
Available in Apple stores (EMEA and Australia / New Zealand) in July
Available in retail stores around the world in the coming months.
MSRP $149.95 USD
IMAGERY
Images of all products are available for download HERE .
About Belkin
Belkin is an accessories market leader delivering power, protection, productivity, connectivity and audio solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018, Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.
© 2022 Belkin International, Inc. and/or its affiliates. All rights reserved.
All product names, logos, and brands are property of their respective owners.
_____________________________________
* Fast charging is only compatible with Apple Watch Series 7. Other models will have regular charge times.
** Based on testing conducted by Belkin in October 2021 using Apple Watch Series 7 (GPS) 45mm Aluminum with Sport band and Apple Watch Series 6 44mm Aluminum with Sport band (GPS), all devices tested with watchOS 8.0.1 software, Belkin BOOSTCHARGE PRO Portable Fast Charger for Apple Watch/Belkin BOOSTCHARGE PRO 3-in-1 Wireless Charging Pad with MagSafe and Apple 20W USB-C Power Adapter (Model A2305). Charge time varies with region, settings, and environmental factors; actual results will vary.
*** For iPhone 13 mini and iPhone 12 mini, MagSafe charging delivers up to 12W of peak power delivery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom